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Background: Colorectal cancer remains one of the leading causes of cancer death worldwide. Traditional Chinese
Medicine (TCM) has played a positive role in colorectal cancer treatment. There is a great need to establish effective
herbal formula for colorectal cancer treatment. Based on TCM principles and clinical practices, we have established
an eight herbs composed formula for colorectal cancer treatment, which is Teng-Long-Bu-Zhong-Tang (TLBZT). We
have demonstrated the anticancer effects of TLBZT against colorectal carcinoma in vitro. In present study, we
evaluated the anticancer potential of TLBZT, used alone or in combination with low dose of 5-Fluorouracil (5-Fu),
in CT26 colon carcinoma in vivo.
Methods: CT26 colon carcinoma was established in BALB/c mice and treated with TLBZT, 5-Fu, or TLBZT plus 5-Fu.
The tumor volumes were observed. Apoptosis was detected by TUNEL assay. Caspases activities were detected by
colorimetric assay. Cell senescence was indentified by senescence β-galactosidase staining. Gene expression and
angiogenesis was observed by immunohistochemistry or western blot.
Results: TLBZT significantly inhibited CT26 colon carcinoma growth. TLBZT elicited apoptosis in CT26 colon
carcinoma, accompanied by Caspase-3, 8, and 9 activation and PARP cleavage, and downregulation of XIAP and
Survivin. TLBZT also induced cell senescence in CT26 colon carcinoma, with concomitant upregulation of p16 and
p21 and downregulation of RB phosphorylation. In addition, angiogenesis and VEGF expression in CT26 colon
carcinoma was significantly inhibited by TLBZT treatment. Furthermore, TLBZT significantly enhanced anticancer
effects of 5-Fu in CT26 colon carcinoma.
Conclusions: TLBZT exhibited significantly anticancer effect, and enhanced the effects of 5-Fu in CT26 colon
carcinoma, which may correlate with induction of apoptosis and cell senescence, and angiogenesis inhibition.
The present study provides new insight into TCM approaches for colon cancer treatment that are worth of
further study.
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Colorectal cancer is the third most commonly diagnosed
cancer in males and the second in females worldwide.
The incidence of colorectal cancer is increasing due to
smoking, lack physical activities, overweight and obesity,
red and processed meat consumption, and excessive al-
cohol consumption [1]. The current treatment of colo-
rectal cancer mainly depends on surgery, chemotherapy,
radiotherapy and targeted therapy. However, the curative
effect of these treatments are less than satisfactory, the
5-year overall survival after resection for colon cancer is
about 60% [2], the 5-year survival for metastatic colorec-
tal cancer is only approximately 10% [3]. Colorectal can-
cer remains the fourth leading cause of cancer death in
men and the third in women worldwide [1]. Clearly, de-
velopment of novel approach for colorectal cancer treat-
ment is highly warranted.
In China, Traditional Chinese Medicine (TCM) has
played a positive role in colorectal cancer treatment. TCM
has been confirmed to effectively enhance curative effects
and reduce toxic side effects of chemotherapy, palliate
clinical syndrome, prevent recurrence and metastasis, im-
prove quality of life and immune function, and prolong
survival time in colorectal cancer [4]. The personalized
TCM therapy is Syndrome Based Differential Treatment.
In Chinese herbalism, every herb has its own characteris-
tics. Diseases can be effectively treated by combining
herbs based on their various features. Combinations of
multiple herbs guided by TCM theories, called Chinese
herbal formula, are the major application form of Chinese
herb. Due to the lack of appropriate ancient Chinese
herbal formula for cancer, most TCM physicians combine
multiple herbs for a formula or prescription based on the
patient’s illness and body condition, TCM principles,
pharmacological studies and personal experience [5].
There is a great need to establish effective herbal formula
for colorectal cancer treatment.
According to the TCM theories and clinical observa-
tions, the pathogenesis of colorectal cancer is related to
damp-heat, toxicity accumulation, and spleen-deficiency
[4,6,7]. Based on the therapeutic method of clearing
heat-toxicity, eliminating dampness and tonifying Pi
(spleen), and the modern principle of anticancer and
anti-angiogenesis, and TCM clinical practices, we have
established an eight herbs composed formula for colorec-
tal cancer treatment, which is Teng-Long-Bu-Zhong-Tang
(TLBZT). We have demonstrated TLBZT may inhibit
proliferation, activate Caspases to induce apoptosis,
upregulate p16 and p21 and downregulate RB phos-
phorylation to induce cell senescence in colon carcin-
oma cells in vitro [8,9]. In present study, we evaluated
the anticancer effects of TLBZT, used alone and in
combination with low dose of 5-Fluorouracil (5-Fu), in
CT26 colon carcinoma in vivo.Methods
Materials
DMEM medium and fetal bovine serum was obtained
from Hyclone (Logan, UT). 5-Fu injection was bought
form Xudong Haipu Pharmaceutical Co., Ltd (Shanghai,
China). FragEL™ DNA Fragmentation Detection Kit was
purchased from EMD Millipore (Darmstadt, Germany).
Senescence β-Galactosidase Staining Kit and PARP anti-
body were from Cell Signaling Technology (Danvers,
MA). Caspase-3, Caspase-8 and Caspase-9 Activity Assay
Kit were obtained from Beyotime Institute of Biotech-
nology (Jiangshu, China). Antibody against p21 was pur-
chases from Boster Bio-engineering Limited Company
(WuHan, China). XIAP, Survivin, GAPDH and pRB
antibodies were purchased from Bioworld Technology
(St. Louis Park, MN). Antibody against p16 was purchased
from Proteintech (Chicago, IL). Antibodies against CD31
and VEGF were the product of from Santa Cruz Biotech-
nology (Santa Cruz, CA).
Preparation of TLBZT
The herbs used in TLBZT formula (Chinese patent
ZL200910197565.2) are the roots of Actinidia chinensis
(Teng-Li-Geng) 30 g, Solanum nigrum (Long-Kui) 15 g,
Duchesnea indica (She-Mei) 15 g, Atractylodes macro-
cephala Koidz (Bai-Zhu) 9 g, Poria cocos (Fu-Ling) 15 g,
Coix seed (Yi-Yi-Ren) 30 g, Mistletoe (Hu-Ji-Sheng) 15 g,
and Scutellaria barbata (Ban-Zhi-Lian) 30 g. All those
herbs were from the herb store in Longhua Hospital
according to the original proportion, and decocted twice
with 8-fold volume of distilled water for 1 hour. The de-
coction were collected, filtered, merged and concen-
trated to 1.5 g/mL (equivalent to crude herb materials),
and stored at 4°C.
For Gas chromatography–mass spectrometry (GC/
MS) analysis, TLBZT were further extracted with
dichloromethane and diethyl ether, and passed through
0.22 μm filter. GC/MS analysis of TLBZT extract was
performed by GCMS6800 (Skyray Instrument, Jiangsu,
China) equipped with a DB-5ms column (30 m × 0.25
mm × 0.25 μm) (Agilent technologies, CA). Helium was
used as carrier gas at a constant flow rate of 1 mL/min.
An injection volume of 1 μL was employed in splitless
mode. Injector and ion-source were maintained at 280°C
and 230°C, respectively. The mass-scan range was
50–500. The GC/MS profile of TLBZT is presented
in Additional file 1: Figure S1.
Cell culture and animal model
Murine colon carcinoma CT26 cells were obtained from
obtained from Cell Bank of Type Culture Collection of
Chinese Academy of Sciences. CT26 cells were grown in
DMEM medium with 10% FBS, penicillin (100 U/mL)
and streptomycin (100 μg/mL) and maintained at 37°C
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weeks old) BALB/c mice (obtained from Shanghai SLAC
Laboratory animal center) were acclimated for one week
and were fed with animal chow and water ad libitum in
SPF animal laboratory of Longhua Hospital.
The mice were injected s.c. with 1 × 106 CT26 cells in
100 μl PBS in the right flank. When the tumors were
palpable, the mice were randomly divided into 4 groups
(n=10 mice/group), and intragastric administered with
TLBZT (22.5 g/kg/0.3 ml, equivalent to crude herb mate-
rials, once a day) or same volume of distilled water, or i.p.
administered with 5-FU (30 mg/kg/0.3 ml, once a week),
or treated with both TLBZT and 5-Fu. Tumor width (W)
and length (L) were measured every 3 days by calipers.
The tumor volume (Tv) was calculated according to the
formula: Tv = 0.52 × L × W2. After three weeks of treat-
ment, the mice were sacrificed, and the tumors were re-
moved, weighed and subjected to further experiments. All
studies involving mice were approved by the Longhua
Hospital Animal Care and Use Committee.
TUNEL assay
Apoptotic cells were identified by TUNEL (terminal
deoxynucleotidyl transferase-mediated nick end labeling)
assay following the manufacturer’s guide. Images were
captured by the Olympus microscope at ×200 magnifica-
tion. The apoptotic cells were counted by Image-Pro
Plus 6.0 software.
Caspases activities assay
The activities of Caspases were detected by Caspase-3, 8
and 9 Activity Assay Kit. According to the manufacturer's
protocol, the tumor samples were homogenized, and the
supernatant were collected and determined protein con-
centration. Then, the supernatant were respectively incu-
bated with Ac-DEVD-pNA (Caspase-3), Ac-IETD-pNA
(Caspase-8) and Ac-LEHD-pNA (Caspase-9) in assay buf-
fer at 37°C for 2 hours. Finally, the production of p-
nitroaniline was monitored by microplate reader at wave-
length of 405 nm.
Senescence β-galactosidase staining
Senescent cells in tumor samples were identified by Senes-
cence β-galactosidase (SA-β-gal) staining was performed
according to the manufacturer's protocol. Images were
captured by Olympus microscope at ×200 magnification
and analyzed by Image-Pro Plus 6.0 software.
Immunohistochemistry
The paraffin-embedded tumor tissues were sectioned
(5 μm), deparaffinized, blocked with 3% hydrogen pero-
xide and washed with PBS. For immunostaining, sec-
tions were probed with antibodies against cleaved PARP
(1:100), XIAP (1:200), Survivin (1:200), p21 (1:200), p16(1:200), pRB (1:200), CD31 (1:100), and VEGF (1:100) at
4°C overnight, followed by incubation with secondary
antibody and visualized using 3,3-diaminobenzidine as
chromagen. Sections were counterstained with hema-
toxylin and mounted with glass coverslips. Images were
captured by the Olympus microscope, and analyzed by
Image-Pro Plus 6.0 software.
Western blot
Western blots were performed as described previously
[9]. Briefly, after three weeks treatment, CT26 carcin-
omas (3 tumors/group) were collected, lysed, combined
and subjected to 8–10% SDS-PAGE gel, and transferred
onto a nitrocellulose membrane (Amersham). The trans-
ferred membrane were blocked with 5% non-fat milk,
washed, and probed with antibodies against cleaved
PARP (1:1000), XIAP (1:1000), Survivin (1:1000), p16
(1:1000), p21 (1:1000), pRB (1:1000), VEGF (1:500) or
GAPDH (1:2000). Blots were then washed and incubated
with IRDye 700- conjugated (1:3000) or IRDye 800-
conjugated (1:5000) secondary antibodies (Rockland
Immunochemicals), and visualized in Odyssey Infrared
Imaging System (LI-COR Biosciences).
Data analysis
Results were expressed as mean ± standard deviation,
and the differences between groups were compared by
one-way ANOVA. Differences were considered signifi-
cant at P<0.05.
Results
TLBZT and 5-Fu inhibited CT26 colon carcinoma growth
To observe the effect of TLBZT on tumor growth, CT26
colon carcinoma was established in BALB/c mice. When
the tumors were palpable, the mice were treated with
TLBZT, 5-Fu, TLBZT plus 5-Fu, or distilled water. As
shown in Figure 1, tumors grew progressively in control
group. TLBZT or 5-FU significantly inhibited CT26 colon
carcinoma growth as demonstrated by tumor volume and
tumor weight (P < 0.01). TLBZT combined with 5-Fu sig-
nificantly increased the effects in inhibiting tumor growth
than either treatment alone (P < 0.01).
TLBZT and 5-Fu induced apoptosis in CT26 colon
carcinoma
After three weeks of treatment, the tumor were collected
and embedded with paraffin. The apoptotic tumor cells
were determined by the TUNEL assay. As shown in
Figure 2, TUNEL positive cells were represented brown
staining, the TUNEL positive cells were significantly in-
creased in TLBZT and 5-Fu group and compared with
controls (P<0.01). The combination group showed more





































Figure 1 TLBZT and 5-FU inhibited CT26 carcinoma growth.
Female BALB/c mice were injected s.c. with 1 × 106 CT26 cells.
When the tumors were palpable, the mice were randomized to
receive treatment with TLBZT, 5-Fu, TLBZT plus 5-Fu, or distilled
water as a control. Tumor volumes were monitored every three days
(A). After three weeks of treatment, the tumors were removed and
weighed (B). **P<0.01, versus control group, ##P<0.01, versus TLBZT
or 5-Fu group.
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Cell apoptosis is executed by a Caspase cascade [10], so
we further tested Caspase-3, 8 and 9 activities after drug
treatment. As shown in Figure 3A, after three weeks of
treatment, Caspase-3, 8 and 9 were significantly acti-
vated in TLBZT and 5-Fu group and compared with
controls (P<0.01). Combinational treatment with TLBZT
and 5-Fu was showed more effective in Caspase-3, 8 and
9 activation than TLBZT or 5-Fu treatment alone
(P<0.01). In addition, PARP, one of the earliest substratesA Control TLBZT
5-Fu TLBZT + 5-Fu
Figure 2 TLBZT and 5-FU induced apoptosis in CT26 carcinoma. After
to TUNEL assay (3 tumors/group) and observed under microscope (×200) (
each slide. The percentage of apoptosis cells were expressed as means ± S
ΔP<0.05, versus 5-Fu group.of Caspase-3 during apoptosis [11], was cleavaged after
TLBZT or 5-Fu treatment (Figure 3B and C). Cleavaged
PRAP was significantly increased in TLBZT plus 5-Fu
group than TLBZT or 5-Fu group (P<0.01). We also
confirmed PARP cleavage by western blot, the results of
western blot were consistent with immunohistochemis-
try (Figure 3D).
Effects of TLBZT and 5-Fu on XIAP and Survivin
expression
It has been reported inhibitor of apoptosis proteins, such
as XIAP and Survivin are overexpressed in colorectal
cancer [12,13]. We also observed XIAP and Survivin
expression in CT26 colon carcinoma after three weeks
of drug treatment. As shown in Figure 4, XIAP and
Survivin were overexpressed in CT26 colon carcinoma.
TLBZT or 5-Fu treatment significantly inhibited XIAP
and Survivin expression and compare with controls
(P<0.01). TLBZT combined with 5-Fu significantly
increased the inhibitory effects on XIAP and Survivin
expression than either treatment alone (P<0.01).
TLBZT induced cell senescence in CT26 colon carcinoma
We have demonstrated TLBZT may induce cell senes-
cence in colon carcinoma cells in vitro [9], so we further
detected cell senescence in CT26 colon carcinoma after
three weeks of treatment. The senescent cells were identi-























three weeks treatment, CT26 carcinomas were collected and subjected
A). The apoptotic cells were counted in 3 high power fields (HPF) in



















































Figure 3 TLBZT and 5-FU activitied Caspases. After three weeks treatment, CT26 carcinomas (3 tumors/group) were removed, homogenized,
and subjected to Caspase-3, Caspase-8 and Caspase-9 activities assay by cleavage of specific substrate. Caspases activities were expressed as fold
activation over control (A). Cleavage of PARP was detected by immunohistochemistry (3 tumors/group) and observed under microscope (×200)
(B). Cleaved PARP positive cells (3 HPF/slide) were counted by Image-Pro Plus 6.0 software and expressed as percentage of total cells (C). D, PARP
Cleavage in CT26 carcinomas were further verified with western blot by antibody against cleavage PARP (c-PARP). GAPDH was used as a loading
control. **P<0.01, versus control group, ##P<0.01, versus TLBZT or 5-Fu group.
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significant cell senescence in CT26 colon carcinoma com-
pared with controls (P<0.01). To our surprise, cell senes-
cence in 5-Fu treated CT26 colon carcinoma was few
compared with TLBZT (P<0.01) (Figure 5).
Effects of TLBZT cell senescence related gene expression
It has been demonstrated p21, p16 and RB phosphoryl-
ation plays a central role in cell senecescence [15]. We
examined p16, p21 and RB phosphorylation in CT26
colon carcinoma after three weeks of TLBZT treatment
by immunohistochemistry and western blot. As shown
in Figure 6, TLBZT significantly upregulated p16 and
p21 expression, and downregulated RB phosphorylation
in CT26 colon carcinoma and compared with controls
(P<0.01).
TLBZT inhibited angiogenesis and VEGF expression
Some herbs in TLBZT, such as Scutellaria barbata
and Mistletoe have been reported to possess anti-angiogenesis potential [16-19]. We suppose that the re-
duction of tumor growth by TLBZT treatment may be
partially involved in the inhibition of angiogenesis.
Angiogenesis within CT26 colon carcinoma tissue was
estimated by immunohistochemistry with an antibody
reactive to CD31 as an endothelial marker [20,21]. The
result showed TLBZT treatment resulted in apparent
inhibition of angiogenesis in CT26 colon carcinoma com-
pared with control groups (P<0.01). In addition, expres-
sion of VEGF was also significantly inhibited by TLBZT
treatment compared with control group (P<0.01).
(Figure 7).
Discussion
In TCM, the principle of combining herbs for a Chinese
herbal formula is monarch, minister, assistant and guide
(Jun, Chen, Zuo and Shi) [5,22]. The monarch herb(s)
are the key ingredient in the formula to target the pri-
mary cause or syndrome. Minister herb(s) are used to












































Figure 4 Effects of TLBZT and 5-FU on XIAP and Survivin expression. After three weeks treatment, expression of XIAP and Survivin in CT26
carcinoma (3 tumors/group) were detected by immunohistochemistry and observed under microscope (×200) (A). The mean optical density
(MOD) of XIAP and Survivin (3 HPF/slide) were analyzed by Image-Pro Plus 6.0 software, and expressed as fold of control (B). C, expression of
XIAP and Survivin in CT26 carcinomas were further verified with western blot by specific antibody. GAPDH was used as a loading control.
**P<0.01, versus control group, ##P<0.01, versus TLBZT or 5-Fu group.
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to reinforce the curative effect of the Monarch or Minis-
ter herb(s), or allay the drastic and toxic effect of the
Monarch or Minister herb(s). While the Guide herb(s)
are applied to harmonize and integrate the effects of
other herbs, or direct the formula to act on the target
meridian or the offending part of body. However, Guide
herb(s) are not indispensable for a formula, based on the
specific conditions, Guide herb(s) might be used or not
used in a formula.
According to the TCM theories, Actinidia chinensis, So-
lanum nigrum and Duchesnea indica are used to against
the pathogenic factors of damp-heat and toxicity accumu-
lation, and served as Monarch herbs in TLBZT. In
addition to traditional herbal efficacy, Actinidia chinensis,
Solanum nigrum and Duchesnea indica also have been
proved anticancer potential. It has been reported ethanol
extracts from Actinidia chinensismay inhibit colon carcin-
oma LoVo cells and HT-29 cells proliferation, and induce
apoptosis in LoVo cells accompanied by Bcl-2/Bax
downregulation and Caspase-3 upregulation [23,24].
Components of Solanum nigrum, such as solamargine,Solanine, polysaccharide and polyphenol-rich extract of
Solanum nigrum have demonstrated anticancer effects
against various cancer cells [25-28]. Phenolic extract of
Duchesnea indica can inhibit cervical and ovarian cancer
growth through induction of apoptosis and cell cycle
arrest [29,30].
Atractylodes macrocephala Koidz, Poria cocos and
Coix seed are used as Minister herbs to target spleen-
deficiency, damp and the loss of appetite induced by long-
term use of Monarch herbs. In addition to traditional
efficacy of tonifying Pi (spleen), Atractylodes macrocephala
Koidz, Poria cocos and Coix seed or their components also
have been showed anticancer effects against cancer cells.
Atractylodes macrocephala Koidz extract may inhibit S180
tumor growth [31]. Poricotriol A from Poria cocos may in-
duce apoptosis in leukemia HL-60 cells and lung cancer
A549 cells [32]. Pachymic acid from Poria cocos may re-
duce cell proliferation and induced apoptosis through
mitochondria dysfunction in prostate cancer cells [33].
Kanglaite injection, a Coix seed extract, has been widely
used as anticancer drug in Chinese oncological clinical










































Figure 5 Effects of TLBZT and 5-FU on cell senescence in CT26 carcinoma. A, after three weeks treatment, CT26 carcinomas (3 tumors/
group) were removed and frozen cut into 7μm sections, fixed, reacted with SA-β-gal staining solution overnight and observed under microscope
(×200). B, SA-β-gal positive staining was counted in 3 HPF in each slide and expressed as fold over control. **P<0.01, versus control group,
##P<0.01, versus TLBZT group, #P<0.05, versus TLBZT group.
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coixspirolactam E, coixspiroenone, coixspirolactam A, co-
ixspirolactam C, coixlactam, and ficusal, may significantly
inhibite breast cancer cells proliferation [35].
Scutellaria barbata and Mistletoe are Assistant herbs









Figure 6 Effects of TLBZT on cell senescence related gene expression
CT26 carcinomas (3 tumors/group) were detected by immunohistochemist
phosphorylation positive cells (3 HPF/slide) were counted by Image-Pro Plu
expression and RB phosphorylation was further detected with western blot
versus control group.by their anti-angiogenesis and anticancer effects. It has
been reported Scutellaria barbata may inhibit angiogen-
esis in vitro and in colorectal cancer model via sup-
pression of Hedgehog pathway and VEGF [16,17].
Scutellaria barbata extract also have been showed


























. After three weeks treatment, p16 and p21, and RB phosphorylation in
ry and observed under microscope (×200) (A). The p21, p16 and RB
s 6.0 software, and expressed as mean ± SD (B). C, p16 and p21
by specific antibody. GAPDH was used as a loading control. **P<0.01,


































Figure 7 Effects of TLBZT and 5-FU on angiogenesis. A, after three weeks treatment, angiogenesis and VEGF expression in CT26 carcinomas
(3 tumors/group) were detected by immunohistochemistry and observed under microscope (×200). B, vessel density was determined via
counting the number of the microvessels per high-power field (3 HPF/slide), and the MOD of VEGF (3 HPF/slide) were analyzed by Image-Pro
Plus 6.0 software, and expressed as fold over control. C, VEGF expression in CT26 carcinomas were further verified by western blot. GAPDH was
used as a loading control. **P<0.01, versus control group. ▲P>0.05, versus control group.
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endothelial cells and inhibit angiogenesis [18,19]. In
addition, Mistletoe lectins could inhibit proliferation and
induce apoptosis in colon cancer HT-29 cells [37].
TLBZT is an herbal formula fitted with both TCM the-
ories and the principle of anticancer. In present study,
we observed TLBZT, alone or in combination with 5-Fu,
significantly inhibited CT26 colon carcinoma growth ac-
companied by apoptosis.
Apoptosis is an evolutionarily conserved cell suicide
process that acts to balance mitosis in the development
and maintenance of tissue homeostasis for the removal
of superfluous, transformed or damaged cells, and has
been recognized as a popular target for anticancer ther-
apy [10,38,39]. Two major pathways have been identified
in the process of apoptosis. In extrinsic death receptor
pathway, the death ligands (FasL, TRAIL, etc.) binds to
the death receptors (FAS, TRAIL-R, etc.) which recruits
adaptor proteins, such as Fas-associated death domain
(FADD), to form ligand-receptor-adaptor protein com-
plex (known as the death-inducing signalling complex,
DISC), and then activists Caspase-8, followed byCaspase-3 activation and apoptosis. The intrinsic path-
way involves the signals to mitochondria which lead to
release of cytochrome C from mitochondria. Released
Cytochrome C combines Apaf-1 and Caspase-9 to form
apoptosome and activates Caspase-9 which in turn acti-
vates Caspases-3, causing the cell to undergo apoptosis.
As the members of inhibitor of apoptosis proteins
(IAPs), XIAP and Survivin are overexpressed in colorec-
tal cancer, and have been recognized as diagnostic
markers and therapeutic targets [12,13,40]. XIAP and
Survivin may inhibit activation of Caspases, down-
regulation of XIAP and Survivin could sensitize colorec-
tal cancer cell to drug induced apoptosis [41,42]. In
present study, TLBZT alone or in combination with 5-
Fu, significantly induced apoptosis in CT26 colon car-
cinoma, accompanied by Casapse-3, 8 and 9 activation,
and downregulation of XIAP and Survivin, suggested
casapses activation and downregulation of XIAP and
Survivin may contribute to TLBZT and 5-Fu induced
apoptosis.
In addition to apoptosis, cell senescence also contrib-
utes to cancer therapeutic response, and has been
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escence is a state of stable irreversible cell cycle arrest
and loss of proliferative capacity. Senescent cell main-
tains some metabolic activity but no longer proliferates,
and exhibits increased SA-β-gal activity at an acidic pH.
Positive of SA-β-gal staining at an acidic pH has been
identified as biomarker of cell senescence since 1995
[14]. Cell senescence is closely related to the activation
of the CDKN2a (p16INK4A)/pRB or CDKN1a (p21WAF-1/
Cip1)/pRB signaling pathway [15,43-45]. The CDK4 and
CDK6 inhibitor p16 participates in regulation of RB
phosphorylation, induces cell cycle arrest, and contrib-
utes to the induction of cell senescence. p21, an import-
ant cell cycle regulator, inhibits a variety of cyclin/CDK
complexes, resulted in hypophosphorylation or dephos-
phorylation of RB protein which binds to E2F and pre-
vents it from activating target genes that are essential in
the cell cycle, usually leading to cell cycle arrest. It have
been reported natural products, such as Ganoderiol F,
Antrodia camphorata extract, Liver-Yin tonifying herbs
can inhibit cancer cell growth via cell senescence
[46-48]. In present study, TLBZT significantly increased
SA-β-gal activity accompanied by an increase in p16
and p21, and downregulation of RB phosphorylation,
suggested that TLBZT may induce cell senescence in
CT26 carcinoma and related to upregulation of p16 and
p21 and downregulation of RB phosphorylation.
Angiogenesis, the process of new blood vessel gener-
ate from existing vessels, plays a crucial role in tumor
growth and metastasis. Angiogenesis has been recog-
nized as an impotent therapeutic target for cancer treat-
ment since it first proposed by Judah Folkman in 1971
[49]. Currently, angiogenesis targeted drugs, such as
bevacizumab (monoclonal antibody against VEGF),
sorafenib, sunitinib, pazopanib and everolimus have
been wildly used in clinical. CD31 or platelet/endothe-
lial cell adhesion molecule-1(PECAM-1) is a widely
used marker protein for angiogenesis [20,21]. VEGF, se-
creted by cancer cells, vascular endothelial cells or
tumor associate macrophages, is a major driver of
tumor angiogenesis [50,51]. By stimulating vascular
endothelial cells proliferation, VEGF can trigger angio-
genesis and promote tumor growth. In present study,
we detected TLBZT significantly inhibited angioge-
nesis in CT26 colon carcinoma with concomitant
downregulation of VEGF, suggested that anti-angi-
ogenesis may contribute to TLBZT mediated anticancer
effects. In TLBZT, Actinidia chinensis [52], Solanum
nigrum [53], Duchesnea indica [54], Scutellaria barbata
[16,17], and Mistletoe [18,19] or their ingredients have
been demonstrated anti-angiogenesis effects. The com-
ponents and the precise mechanism responsible for
TLBZT induced anti-angiogenesis effects need to be
further explored.Conclusion
Our study demonstrated that TLBZT exhibited signifi-
cantly anticancer effect, and enhanced the effects of 5-
Fu in CT26 colon carcinoma, which may correlate with
induction of apoptosis and cell senescence, and angio-
genesis inhibition. The present study provides new
insight into TCM approaches for colon cancer treatment
that are worth of further study.
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